Exchange: NASDAQ·Updated 07:59 PM EDT
ROIV logo

ROIVRoivant Sciences Ltd

$35.01
$0.09
(0.26%)
Today
Closed $35.01
$0.00
(0.00%)
After Hours
EarningsAug 6
Mkt Cap$25.18B
Vol4.04M
News
all
press releases
ABUS Stock Rallies Ahead Of Big Payout From Moderna Settlement This Week
Arbutus expects to receive around $179 million from Moderna.
Stocktwits
More News
Could Roivant Sciences Be a Multibagger Stock Over the Next 5 Years?
Key PointsRoivant Sciences anticipates three commercial launches over the next few years, led by brepocitinib...
Nasdaq News: Markets
Biotech and Biologics Break Out: These Tiny Stocks Are Suddenly Dominating the Market Conversation
Emerging biotech and biologics names exploded onto traders’ radar Wednesday as a wave of clinical milestones, regulatory momentum, strategic acquisitions, and high-volume technical breakouts fueled aggressive speculation across the sector. $HCWB, $TGNT, $KBLB, $SLS, $RKDA, $ROIV, $SLXN
24-7 Market News
TAT Technologies Posts Upbeat Q1 Earnings, Joins Roivant Sciences, Immunitybio And Other Big Stocks Moving Higher On Wednesday
TAT Technologies Ltd (TATT) reported better-than-expected Q1 results, sending shares up 11.7%. Other big gainers include IMVT, SLS, TE, VUZI, ROIV, POET, ARM, AMC, ALAB, DSGN, and TLN.read more...
Benzinga
Roivant Sciences Reports Q4 2026 Results: Full Earnings Call Transcript
read more...
Benzinga
ROIV Stock Nears Record High: Moderna Settlement Drives Q4 Profit, But Pipeline Catalysts Keep Retail Interested
The biotech firm delivered a fourth-quarter profit compared to loss estimates and unveiled promising milestone updates across its autoimmune disease pipeline.
Stocktwits
Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Misses Revenue Estimates
Montes Archimedes Acquisition (ROIV) delivered earnings and revenue surprises of -41.18% and -8.56%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Montes Archimedes Acquisition (ROIV) Upgraded to Buy: Here's Why
Montes Archimedes Acquisition (ROIV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks
Gossamer Bio (GOSS) Reports Q1 Loss, Tops Revenue Estimates
Gossamer Bio (GOSS) delivered earnings and revenue surprises of -17.65% and +181.04%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Invivyd, Inc. (IVVD) Reports Q1 Loss, Lags Revenue Estimates
Invivyd, Inc. (IVVD) delivered earnings and revenue surprises of -62.50% and -25.30%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
<
1
2
...
>

Advertisement|Remove ads.